CYRX Stock Cryoport, Inc.
STRONG BUY US · NasdaqCMCell and gene therapy logistics recovery offers significant operating leverage and catalyst potential.
Future value: $26.00 (+46.15%) · 6-12 months
Signal breakdown
- ▸BTIG reiterated Buy and raised target to $26.
- ▸Above 50-day MA (+6.06%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (91.5% of range) — strength
- ▸~46% upside to price target
Is CYRX a buy right now?
Trend: CYRX is trading above the 50-day average (+6.08%), RSI 48 — neutral momentum, with a 3-month return of +17.27%.
Valuation & quality: Cryoport, Inc. trades on forward P/E -26.8, PEG 62.13, price-to-book 2.03; fundamentals show net margin -20.1%, return on equity -6.5%, revenue growth 7.7% year on year.
Analyst consensus: 9 analysts have a mean 12-month price target of $19.78 (+11.2% vs the last close; range $15.00 – $26.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 6) — Cell and gene therapy logistics recovery offers significant operating leverage and catalyst potential.
Computed from end-of-day data; not personal advice.
Our track record with CYRX
First flagged in our daily picks as STRONG BUY on 2026-10-27 at $17.79.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -1.70% | +23.90% | +52.90% | +0.10% | -3.90% | +6.00% | +8.70% | +2.20% |
Fundamentals
Analyst price target
Technical signals
About Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Sector: Industrials · Industry: Integrated Freight & Logistics · United States · 684 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.